Circadian owns Vegenics

By Dylan Bushell-Embling
Thursday, 14 August, 2008

Circadian Technologies [ASX: CIR] is now the sole owner of Vegenics, having completed the acquisition of the company today.

Circadian announced the planned acquisition on July 15. Prior to that point, the company held a 66 per cent stake in Vegenics.

Among the intellectual property Circadian has assumed control of are the proteins VEGF-C and VEGF-D, which if blocked may inhibit rumour growth and prevent the spread of new cancer cells.

Circadian has also acquired Vegenics' product pipeline, including drug candidates based on the VEGF-C and VEGF-D protein IPs.

Content from other channels on our network

Carbon-conversion technology creates chemicals for jet fuel

Novel energy storage system to decarbonise buildings

F-Gas Regulation: Turning necessity into opportunity

Tiny gold spheres could improve solar energy harvesting

Methane reduction trial uses nature-based supplement

REDFEB highlights the impacts of chronic stress on the heart

Teachers Health Group announces Simone Tregeagle as next CEO

Pathways to proof: could this transcranial treatment ease chronic pain?

New public hospital funding deal "will not be enough", doctors warn

St Vincent's Hospital faces two charges after patient death

Afnor acquires HACCP Australia and HACCP International

Solving the limitations for paper packaging with coating strategy

Packserv expands into the US with its packaging machinery

Keeping PEZ tablets rolling consistently with print upgrade

Food-grade upscaling line for 'new food' developments

Circadian owns Vegenics

Farm animals and aquaculture cryopreservation partnership announced

Babies of stressed mothers likely to get their teeth earlier

Customised immune cells used to fight brain cancer

Content from other channels on our network